Evidence map›Paper›PMID 28341983›Full record

ReviewHerz2018

[Management of different cardiovascular risk factors with a combination tablet (polypill)].

P Bramlage, W März, D Westermann, B Weisser, J H Wirtz, U Zeymer, P Baumgart, G van Mark, U Laufs, B K Krämer and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 2 countries.

P BramlageInstitut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland. peter.bramlage@ippmed.de.ORCID http://orcid.org/0000-0003-4970-2110
W MärzMedizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Deutschland.
D WestermannKlinik und Poliklinik für Allgemeine und Interventionelle Kardiologie, Universitätsklinikum Eppendorf, Hamburg, Deutschland.
B WeisserInstitut für Sportwissenschaft, Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland.
J H WirtzKardiologische Gemeinschaftspraxis, Dinslaken, Deutschland.
U ZeymerMedizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Deutschland.
P BaumgartMedizinische Klinik I, Clemenshospital Münster, Akad. LKH der Universität Münster, Münster, Deutschland.
G van MarkInstitut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland.
U LaufsKlinik für Innere Medizin III, Universitätsklinikum des Saarlands, Homburg/Saar, Deutschland.
B K KrämerMedizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Deutschland.
T UngerCARIM School for Cardiovascular Diseases, Maastricht University, PO Box 616, 6200 MD, Maastricht, Niederlande.
IPPMed (Germany) · DEChristian-Albrechts-Universität zu Kiel · DEClemenshospital Münster · DEHeidelberg University · DEPraxis für Humangenetik · DEStiftung Institut für Herzinfarktforschung · DEUniversität Hamburg · DEUniversitätsklinikum des Saarlandes · DEUniversity of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe multifactorial origin of cardiovascular diseases has led to polypharmacy in primary and secondary prophylaxis with evidence-based medications, such as statins, antihypertensive drugs and platelet aggregation inhibitors. The number of prescribed drugs correlates inversely to adherence and can lead to treatment failure. Fixed-dose combination drugs (polypills) could increase the medication adherence of patients, reduce risks and prevent cardiovascular events.

methodsThis review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library. The clinical database ClinicalTrials.gov. was also considered.

resultsIn the studies on primary prevention conducted to date, fixed-dose combinations showed a superior control of risk factors, e.g. hypertension and low-density lipoprotein (LDL) cholesterol compared to placebo and at least non-inferiority compared to usual care. In secondary prevention, the effect of the polypill is mostly on the reduction of blood pressure and LDL cholesterol in non-adherent patients; however, evidence that fixed-drug combinations reduce cardiovascular morbidity and mortality compared to standard therapy is lacking.

conclusionThe polypill can be considered as an alternative to polypharmacy after a risk-benefit assessment, especially in non-adherent patients. Ongoing studies are investigating the effect of the polypill on cardiovascular events. Current polypills are limited by the lack of sufficient dosages of the individual components to avoid overtreatment and undertreatment at the individual treatment level.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesDrug CombinationsHydroxymethylglutaryl-CoA Reductase InhibitorsAntihypertensive AgentsHumansRisk FactorsTabletsAntihypertensive AgentsCardiovascular AgentsDrug CombinationsHydroxymethylglutaryl-CoA Reductase InhibitorsTabletsCardiovascular preventionLDL cholesterolPlatelet aggregation inhibitorsPolypillSystolic blood pressure

Identifiers

PMID28341983
OpenAlexW2603587733

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.